|
HUOCA-II (1987)
|
51
|
Ovary
|
46 (mode)
|
24, 28
|
Yes
|
-
|
Tumor angiogenesis factor
|
|
RMG-I (1988)
|
34
|
Ascites
|
47 (mode)
|
60
|
Yes
|
BFP, ferritin, PLAP
|
-
|
|
OCC1 (1990)
|
47
|
Ascites
|
70–77
|
36, 38
|
Yes
|
-
|
Production of CA125
|
|
RMG-II (1991)
|
53
|
Ascites
|
hypertetraploid
|
58
|
No
|
CA125, TPA, MA602-1, MA602-6
|
Production of CA125, TPA, MA602-1, MA602-6
|
|
OVISE (1995)
|
40
|
Metastatic tumor
|
62 (59–65)
|
60
|
Yes
|
CA125, CA19-9, EGFR, ER(−), PgR(−)
|
Production of CA19-9, CA125, TPA
|
|
OVTOKO (1995)
|
78
|
Metastatic tumor
|
78 (76–83)
|
70
|
Yes
|
EGFR, ER(−), PgR(−)
|
-
|
|
JHOC-5 (1999)
|
47
|
Ovary
|
74–85
|
52
|
No
|
-
|
CA125
|
|
JHOC-6 (1999)
|
43
|
Recurrent tumor
|
46–49
|
70
|
Yes
|
-
|
CA125
|
|
SMOV-2 (1999)
|
46
|
Tumor
|
85–92
|
48.2
|
Yes
|
-
|
p53 mutation (−)
|
|
TAYA (2002)
|
43
|
Ascites
|
69–74
|
50
|
No
|
-
|
p53 Exon5 point mutation, PTEN mutation (−)
|
|
RMG-V (2005)
|
52
|
ascites
|
83 (77–85)
|
15.5
|
No
|
-
|
-
|
|
TU-OC-1 (2013)
|
65
|
Ovary
|
64–69
|
38.4
|
Yes
|
-
|
PIK3CA mutation (+)
|
|
HCH-1
|
67
|
Ovary
|
39–44
|
48.7, 66.4
|
Yes
|
CA125, CA19-9, ER(−), PgR(−)
|
production of CA19-9, CA125, TPA
|
